Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Treosulfan,Fludarabine Phosphate
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Medac
Deal Size : Inapplicable
Deal Type : Inapplicable
Medexus Provides Update on Treosulfan NDA Resubmission and Provides Business Update
Details : Trecondyv (treosulfan) is used to prepare patients for blood stem cell transplant. Trecondyv destroys bone marrow cells. This allows for the transplant of new blood stem cells from a donor which leads to the production of healthy blood cells.
Product Name : Trecondyv
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
September 19, 2022
Lead Product(s) : Treosulfan,Fludarabine Phosphate
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Medac
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Treosulfan,Fludarabine Phosphate
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Medac
Deal Size : Inapplicable
Deal Type : Inapplicable
Treosulfan Pivotal Study Results Published
Details : Study found event-free survival and overall survival superior after Trecondyv (treosulfan) compared to RIC busulfan, also found non-relapse mortality lower in treosulfan arm than busulfan arm.
Product Name : Trecondyv
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
June 06, 2022
Lead Product(s) : Treosulfan,Fludarabine Phosphate
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Medac
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Treosulfan,Fludarabine Phosphate
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Medac
Deal Size : Inapplicable
Deal Type : Inapplicable
Medexus Pharmaceuticals Provides Update on Resubmission of Treosulfan NDA
Details : Trecondyv (treosulfan), preparative regimen for allogeneic hematopoietic stem cell transplantation to be used in combination with fludarabine, is medication given to people before they have bone marrow transplant from a donor allogeneic hematopoietic ste...
Product Name : Trecondyv
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
May 25, 2022
Lead Product(s) : Treosulfan,Fludarabine Phosphate
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Medac
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Treosulfan,Fludarabine Phosphate
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Medexus Pharmaceuticals Announces Resubmission of Treosulfan NDA
Details : The resubmission includes additional clinical data and statistical analysis relating to previously-completed phase 3 clinical trial of Treosulfan as well as an update of integrated summary of safety, which FDA had requested in their July 2021 Complete Re...
Product Name : Trecondyv
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
April 22, 2022
Lead Product(s) : Treosulfan,Fludarabine Phosphate
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Recombinant Coagulation Factor Ix
Therapeutic Area : Genetic Disease
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Medexus reached the 50% enrollment target in its Phase 4 clinical trial investigating IXINITY® as a prophylactic treatment for pediatric patients under 12 years of age with hemophilia B.
Product Name : Ixinity
Product Type : Protein
Upfront Cash : Inapplicable
November 16, 2020
Lead Product(s) : Recombinant Coagulation Factor Ix
Therapeutic Area : Genetic Disease
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Triamcinolone Acetonide
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : TH is the longest acting corticosteroid for intra-articular injection, often lasting twice as long as comparator products.
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
September 07, 2020
Lead Product(s) : Triamcinolone Acetonide
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Triamcinolone Acetonide
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Triamcinolone Hexacetonide Injectable Suspension 20 mg/mL (TH) has been approved for inclusion as a general benefit (open listing) on the List of Medications- Institutions administered by the Régie de l’assurance maladie du Québec (RAMQ), effective A...
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
August 24, 2020
Lead Product(s) : Triamcinolone Acetonide
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable